AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.47 |
Market Cap | 222.82M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.16 |
PE Ratio (ttm) | -9.16 |
Forward PE | n/a |
Analyst | Buy |
Ask | 1.55 |
Volume | 1,198,692 |
Avg. Volume (20D) | 3,196,039 |
Open | 1.57 |
Previous Close | 1.54 |
Day's Range | 1.46 - 1.58 |
52-Week Range | 1.04 - 3.93 |
Beta | undefined |
About HRTX
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acut...
Analyst Forecast
According to 3 analyst ratings, the average rating for HRTX stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 309.56% from the latest price.
Next Earnings Release
Analysts project revenue of $37.37M, reflecting a 9.16% YoY growth and earnings per share of -0.03, making a -57.14% decrease YoY.
2 months ago · seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q3 2024 Earnings Call TranscriptHeron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Melissa Jarel - Executive Director Craig Collard - Chief Executive Officer Ir...